APLS Projected Dividend Yield
Apellis Pharmaceuticals Inc ( NASDAQ : APLS )Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Co.'s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. 21 YEAR PERFORMANCE RESULTS |
APLS Dividend History Detail APLS Dividend News APLS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |